Jerzy Jakubowicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9481627/publications.pdf

Version: 2024-02-01

933447 713466 34 477 10 21 g-index citations h-index papers 34 34 34 753 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comparison between Breast MRI and Contrast-Enhanced Spectral Mammography. Medical Science Monitor, 2015, 21, 1358-1367.	1.1	104
2	Malignant Phyllodes Tumor of the Breast: Treatment and Prognosis. Breast Journal, 2014, 20, 639-644.	1.0	67
3	Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity. Lung Cancer, 2011, 71, 344-349.	2.0	55
4	Degree of Enhancement on Contrast Enhanced Spectral Mammography (CESM) and Lesion Type on Mammography (MG): Comparison Based on Histological Results. Medical Science Monitor, 2016, 22, 3886-3893.	1.1	36
5	Pure and Mixed Mucinous Carcinoma of the Breast: A Comparison of Clinical Outcomes and Treatment Results. Breast Journal, 2016, 22, 529-534.	1.0	34
6	Original paper Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. Polish Journal of Pathology, 2015, 2, 133-141.	0.3	25
7	Tumour cell kinetics as a prognostic factor in squamous cell carcinoma of the cervix treated with radiotherapy. Radiotherapy and Oncology, 1999, 50, 77-84.	0.6	17
8	Current treatment options of brain metastases and outcomes in patients with malignant melanoma. Reports of Practical Oncology and Radiotherapy, 2016, 21, 271-277.	0.6	15
9	Postoperative irradiation in patients with pT3-4N0 laryngeal cancer: results and prognostic factors. European Archives of Oto-Rhino-Laryngology, 2015, 272, 673-679.	1.6	13
10	Hematogenous metastases in patients with Stage I or II endometrial carcinoma. Strahlentherapie Und Onkologie, 2011, 187, 806-811.	2.0	12
11	Palliative thoracic radiotherapy for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer, 2015, 87, 130-135.	2.0	12
12	Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. Journal of Ovarian Research, 2016, 9, 11.	3.0	10
13	Survival of breast cancer patients according to changes in expression of selected markers between primary tumor and lymph node metastases. Biomarkers in Medicine, 2016, 10, 219-228.	1.4	10
14	Effect of definitive radiotherapy on the long-term outcome in patients with solitary extramedullary plasmacytoma. Hematological Oncology, 2017, 35, 317-322.	1.7	10
15	Comparison of the sensitivity and specificity of real-time PCR and <i>in situ</i> hybridization in HPV16 and 18 detection in archival cervical cancer specimens. Folia Histochemica Et Cytobiologica, 2012, 50, 239-247.	1.5	9
16	Androgen receptor in male breast cancer. Polish Journal of Pathology, 2015, 4, 347-352.	0.3	8
17	Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients. Ecancermedicalscience, 2014, 8, 476.	1.1	7
18	Post-Irradiation Bladder Syndrome After Radiotherapy of Malignant Neoplasm of Small Pelvis Organs: An Observational, Non-Interventional Clinical Study Assessing VESIcare®/Solifenacin Treatment Results. Medical Science Monitor, 2016, 22, 2691-2698.	1.1	6

#	Article	IF	Citations
19	Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy. Reports of Practical Oncology and Radiotherapy, 2016, 21, 31-36.	0.6	5
20	Systemic treatment of non-small cell lung cancer brain metastases. Wspolczesna Onkologia, 2016, 5, 352-357.	1.4	4
21	Synchronous malignancies in patients with breast cancer. Nowotwory, 2018, 67, 336-341.	0.3	4
22	Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy $\hat{a} \in \mathbb{C}$ concomitant boost, with or without concurrent cisplatin, for patients with invasive bladder cancer $\hat{a} \in \mathbb{C}$ clinical outcome. Wspolczesna Onkologia, 2013, 3, 302-306.	1.4	3
23	Radiation therapy complications in patients with primary invasive vaginal carcinoma. Ginekologia Polska, 2013, 84, 206-10.	0.7	3
24	Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity Reports of Practical Oncology and Radiotherapy, 2008, 13, 300-308.	0.6	2
25	Methods and results of locoregional treatment of brain metastases in patients with non-small cell lung cancer. Wspolczesna Onkologia, 2016, 5, 358-364.	1.4	2
26	Rak trzonu macicy – wstępna ocena tolerancji pooperacyjnej pulsacyjnej brachyterapii. Reports of Practical Oncology and Radiotherapy, 2001, 6, 95-98.	0.6	1
27	Classical prognostic factors in patients with non-advanced endometrial cancer treated with postoperative radiotherapy. Reports of Practical Oncology and Radiotherapy, 2006, 11, 169-174.	0.6	1
28	Preoperative radiotherapy does not alter pre- and early postoperative serum CRP and albumin concentrations in colorectal cancer patients. Wspolczesna Onkologia, 2013, 2, 161-164.	1.4	1
29	Methods and results of local treatment of brain metastases in patients with breast cancer. Wspolczesna Onkologia, 2016, 6, 430-435.	1.4	1
30	Histopathological assessment of residual retroperitoneal mass removed in patients after chemotherapy for non-seminomatous germ cell tumours of the testis. Polish Journal of Pathology, 2015, 4, 420-425.	0.3	0
31	Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer. Hereditary Cancer in Clinical Practice, 2016, 14, 4.	1.5	0
32	Rola teleradioterapii w inwazyjnym raku pęcherza moczowego. Nowotwory, 2014, 64, 169-174.	0.3	0
33	Przerzuty raka pęcherza moczowego do prącia — opis trzech przypadków i przegląd piŠmiennictwa. Nowotwory, 2015, 65, 221-224.	0.3	0
34	Proton radiotherapy for treating the most common carcinomas. Nowotwory, 2017, 66, 396-402.	0.3	0